Clinical trial · no report yet · Phase 2
NCT00861705
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
- NCT00861705 ↗
- Completed
- National Cancer Institute (NCI)
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
- Interventions
- Bevacizumab; Carboplatin; Cyclophosphamide; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Paclitaxel
- Arms
- Arm I (paclitaxel, doxorubicin, cyclophosphamide) · Active comparator
- Arm II (paclitaxel, ddAC, bevacizumab) · Experimental
- Arm III (paclitaxel, ddAC, carboplatin) · Experimental
- Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) · Experimental
- Enrollment
- 454
- Primary outcomes
- Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).
- Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 21, 2009
- Primary completion
- Aug 1, 2014
- Results posted
- Yes
- Registry record
- NCT00861705 · updated Jun 29, 2026
Publications
linked from the registry- Radler PD, Felsheim BM, Fernandez-Martinez A, Pfefferle AD, Hayward MC, Singh B, Sikov W, Carey LA, Perou CM. Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance). J Clin Invest. 2026 Aug 4:e205962. doi: 10.1172/JCI205962. Online ahead of print. PubMed 42550611
- Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 Apr 20;40(12):1323-1334. doi: 10.1200/JCO.21.01506. Epub 2022 Jan 19. PubMed 35044810
- Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. PubMed 25092775